En lignende hyppighed af infusionsreaktioner (12, 4%) og behandlingsophør (1, 5%) sås i brystcancer programmet.
A similar incidence of infusion reactions (12.4%) and treatment discontinuation (1.5%) was observed in the breast cancer program.